A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Lung CancerThe purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
18 and up
Participation Criteria
Inclusion Criteria
* Participants must have at least one measurable lesion per response evaluation criteria in solid tumors.
* Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
* Participants must have a life expectancy of at least 3 months at the time of the first dose.
Exclusion Criteria
* Participants must not have any mixed Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) histology.
* Participants must not have any untreated symptomatic central nervous system (CNS) metastases.
* Participants must not have a history of serious recurrent infections.
* Participants must not have a history of severe heart disease.
* Other protocol-defined Inclusion/Exclusion criteria apply.
Study Location
Local Institution - 0025
Local Institution - 0025Montreal, Quebec
Canada
Contact Study Team
Site 0025
Local Institution - 0026
Local Institution - 0026Ottawa, Ontario
Canada
Contact Study Team
Site 0026
Local Institution - 0024
Local Institution - 0024Edmonton, Alberta
Canada
Contact Study Team
Site 0024
Local Institution - 0022
Local Institution - 0022Montréal, Quebec
Canada
Contact Study Team
Site 0022
Local Institution - 0023
Local Institution - 0023Ottawa, Ontario
Canada
Contact Study Team
Centre Hospitalier de l'Université de Montréal
Centre Hospitalier de l'Université de MontréalMontréal, Quebec
Canada
Contact Study Team
Marie Florescu, Site 0022
5148908000Jewish General Hospital
Jewish General HospitalMontreal, Quebec
Canada
Contact Study Team
Jennifer Friedmann, Site 0025
514340822224915- Study Sponsored By
- Bristol-Myers Squibb
- Participants Required
- More Information
- Study ID:
NCT06618287